The current strategy for managing chronic gout is the use of uric-acid-lowering drugs to reduce urate production or of a uricosuric agent to promote renal uric acid excretion. Probenecid is ...

Radiographic scoring of articular damage is useful for evaluating disease progression and response to treatment in patients with rheumatic diseases; currently, however, there is no validated ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

A recent study by researchers from the University of California San Diego and collaborators has uncovered a new molecular ...

Marathon runner Niven Hopkins was diagnosed with stage four chronic kidney disease, discovering that his ‘sore toe’ was ...

Uric acid crystals can accumulate under the skin and form lumps called "tophi." Chronic (long-term) gout can cause knee ...

Among patients with gout in the US, Black individuals and those living in the South were associated with reduced adherence to allopurinol.

Dr Hilary Jones has said that the prevalence of gout is set to increase up to 70 per cent in the coming years - and highlighted symptoms to watch for ...

The third phase, inter-critical gout, is a period between acute attacks when the patient is symptom-free. Finally, chronic ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...